# CAMPO Central Laboratory Core

> **NIH NIH U54** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2023 · $304,553

## Abstract

The California-Mexico-Puerto Rico (CAMPO) Consortium will perform three clinical research studies
focused on the prevention of cervical cancer among HIV-positive women in Mexico and Puerto Rico. Study 1
will examine new screening algorithms for cervical high-grade squamous intraepithelial lesions (HSIL) in 4000
HIV-positive women in Mexico and Puerto Rico. Study 2 will evaluate the impact of anogenital probiotic use on
anal and cervical microbiota profiles and the relationship to anal and cervical HSIL regression in 600 HIVpositive women and men as well as reduction of high-risk HPV DNA persistence among those with no lesions.
Study 3 will evaluate the safety and efficacy of a multivalent replication-defective adenovirus-based
therapeutic HPV vaccine to treat cervical and anal HSIL in 300 HIV-positive women and men and identify
immune response correlates of HSIL regression. Working with the Data Management and Statistics Core, the
Administrative and Coordinating Core, and the Clinical Trials Program, the Central Laboratory Core (CLC) will
perform laboratory assays for each of the three studies. The aims of the CLC are: (1) To perform laboratory
assays required to achieve the primary aims of the clinical research studies conducted within the CAMPO
Consortium’s Clinical Trials Program; (2) To perform laboratory assays for correlative science studies for the
CAMPO Consortium; (3) To expand research capacity of consortium partners in Mexico and Puerto Rico
through technology transfer; (4) To participate in rigorous quality control programs to ensure the validity of
laboratory data; and (5) To support training and career development of early career investigators in laboratorybased research. The CLC will be led by Dr. Alejandro Garcia-Carranca of INCan and co-led by Drs. Filipa
Godoy-Vitorino of UPR and Joel Palefsky of UCSF. Similar to the other CAMPO Cores, the CLC will be
comprised of a network of investigators and facilities across the three Consortium sites, working closely
together but with each site tasked with a role based on their specific expertise. The CLC will have both virtual
and physical components, with CLC laboratory facilities at INCan, INSP and the Condesa Clinic in Mexico, the
University of Puerto Rico Comprehensive Cancer Center, the University of Puerto Rico Clinical Trials Center,
and UCSF. The network will use GlobalTraceTM to track and ship laboratory specimens between the sites. The
CLC will form working groups centered on CAMPO’s scientific agenda- HPV diagnostics, microbiome research
and cellular immunology- with representation from scientists at each site and will participate on CAMPO
Clinical Trials Program study protocol teams. The CLC will perform a rigorous quality assurance program and
report results on a regular basis to CAMPO leadership.

## Key facts

- **NIH application ID:** 10690034
- **Project number:** 5U54CA242646-05
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Teresa Marie Darragh
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $304,553
- **Award type:** 5
- **Project period:** 2019-09-12 → 2025-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10690034

## Citation

> US National Institutes of Health, RePORTER application 10690034, CAMPO Central Laboratory Core (5U54CA242646-05). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10690034. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*